Kirkland & Ellis advised Bristol-Myers Squibb Company on the agreement with Amgen for Amgen to acquire the global rights to Celgene Corporation’s OTEZLA® for $13.4 billion…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
